-       Report 
   - August 2025
    -  193 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                  -       Report 
   - August 2025
    -  192 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                -       Report 
   - May 2025
    -  240 Pages 
    Global
   
   From       €4313EUR$4,799USD£3,783GBP 
                  -       Report 
   - October 2025
    -  189 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                  -       Report 
   - October 2025
    -  188 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                   -       Report 
   - October 2025
    -  188 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                -       Report 
   - May 2025
    -  173 Pages 
    Global
   
   From       €4045EUR$4,500USD£3,547GBP 
                -       Report 
   - February 2025
    -  240 Pages 
    Global
   
   From       €2418EUR$2,690USD£2,120GBP 
                -       Report 
   - November 2025
    -  264 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - July 2025
    -  175 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - April 2025
    -  200 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - January 2025
    -  175 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - November 2025
    -  367 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                  -       Report 
   - October 2025
    -  197 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - January 2025
    -  175 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
             
         Topiramate is a drug used to treat a variety of neurological conditions, including epilepsy, migraine, and bipolar disorder. It is classified as an anticonvulsant and antiepileptic drug, and is used to reduce the frequency of seizures and to prevent migraine headaches. It is also used to treat bipolar disorder, as it can help to reduce the frequency and severity of manic episodes. Topiramate is a member of the Central Nervous System (CNS) drug class, which includes drugs used to treat neurological    conditions.
Topiramate is available in both generic and brand-name formulations, and is available in a variety of dosage forms, including tablets, capsules, and oral solutions. It is typically taken once or twice daily, depending on the condition being treated. Side effects of topiramate include dizziness, drowsiness, and nausea.
The market for topiramate is highly competitive, with a number of major pharmaceutical companies offering the drug. Some of the companies in the market include Pfizer, GlaxoSmithKline, Johnson & Johnson, and Novartis. Show Less   Read more